These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37186491)

  • 1. Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
    van Amersfort K; Vernooij JCM; van der Lee A
    Vet Dermatol; 2023 Oct; 34(5):373-384. PubMed ID: 37186491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of subcutaneous, intralymphatic and sublingual immunotherapy for the long-term control of dogs with nonseasonal atopic dermatitis.
    Fischer NM; Rostaher A; Favrot C
    Vet Dermatol; 2020 Oct; 31(5):365-e96. PubMed ID: 32537789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of intralymphatic immunotherapy (ILIT) on canine atopic dermatitis.
    Timm K; Mueller RS; Nett-Mettler CS
    Vet Dermatol; 2018 Apr; 29(2):123-e49. PubMed ID: 29327474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, double-blinded comparison between subcutaneous rush and intralympathic allergen immunotherapy induction in atopic dogs.
    Mueller RS; Zablotski Y; Baumann K; Boehm T; Kasper B; Klinger C; Monke M; Udraite-Vovk L; Weitzer T; Gedon NKY
    Vet Dermatol; 2023 Apr; 34(2):91-98. PubMed ID: 36424528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hair cortisol concentration, disease severity and quality of life in dogs with atopic dermatitis during lokivetmab therapy.
    Stuart Marques V; Calesso JR; de Carvalho OV; da Costa-Val Bicalho AP
    Vet Dermatol; 2023 Aug; 34(4):339-347. PubMed ID: 37165693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab.
    Calesso JR; Marques VS; de Carvalho OV; Costa-Val AP
    Pol J Vet Sci; 2023 Jun; 26(2):231-238. PubMed ID: 37389418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
    Moyaert H; Van Brussel L; Borowski S; Escalada M; Mahabir SP; Walters RR; Stegemann MR
    Vet Dermatol; 2017 Dec; 28(6):593-e145. PubMed ID: 28906040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intralymphatic immunotherapy: An effective and safe alternative route for canine atopic dermatitis].
    Fischer N; Rostaher A; Favrot C
    Schweiz Arch Tierheilkd; 2016 Sep; 158(9):646-652. PubMed ID: 27655164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
    Michels GM; Ramsey DS; Walsh KF; Martinon OM; Mahabir SP; Hoevers JD; Walters RR; Dunham SA
    Vet Dermatol; 2016 Dec; 27(6):478-e129. PubMed ID: 27647569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
    Marsella R; Ahrens K; Wilkes R; Trujillo A; Dorr M
    Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of immunostimulatory liposome-nucleic acid complexes in allergen-specific immunotherapy of dogs with refractory atopic dermatitis - a pilot study.
    Mueller RS; Veir J; Fieseler KV; Dow SW
    Vet Dermatol; 2005 Feb; 16(1):61-8. PubMed ID: 15725107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of low dose immunotherapy in the treatment of canine atopic dermatitis: a prospective, double-blinded, clinical study.
    Colombo S; Hill PB; Shaw DJ; Thoday KL
    Vet Dermatol; 2005 Jun; 16(3):162-70. PubMed ID: 15960629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double blind, randomized, placebo controlled trial of the efficacy, quality of life and safety of food allergen-specific sublingual immunotherapy in client owned dogs with adverse food reactions: a small pilot study.
    Maina E; Cox E
    Vet Dermatol; 2016 Oct; 27(5):361-e91. PubMed ID: 27426929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis.
    Nishiyama T; Kusakabe M; Imanishi I; Hisano T; Fukamachi T; Taguchi N; Iyori K; Hsiao YH
    Vet Dermatol; 2023 Dec; 34(6):523-531. PubMed ID: 37485602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.
    Van Brussel L; Moyaert H; Escalada M; Mahabir SP; Stegemann MR
    Vet Dermatol; 2021 Oct; 32(5):477-e131. PubMed ID: 34180084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis.
    Loewinger M; Wakshlag JJ; Bowden D; Peters-Kennedy J; Rosenberg A
    Vet Dermatol; 2022 Aug; 33(4):329-e77. PubMed ID: 35644533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the efficacy rate and time-to-efficacy of subcutaneous immunotherapy in dogs with atopic dermatitis.
    Tham HL; Olivry T
    Vet Dermatol; 2022 Apr; 33(2):155-e44. PubMed ID: 34883529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis.
    Szczepanik M; Wilkołek P; Gołyński M; Sitkowski W; Taszkun I; Toczek W
    Vet Dermatol; 2019 Aug; 30(4):330-e93. PubMed ID: 31090122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis.
    Michels GM; Walsh KF; Kryda KA; Mahabir SP; Walters RR; Hoevers JD; Martinon OM
    Vet Dermatol; 2016 Dec; 27(6):505-e136. PubMed ID: 27647513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.
    Souza CP; Rosychuk RAW; Contreras ET; Schissler JR; Simpson AC
    Vet Dermatol; 2018 Dec; 29(6):489-e164. PubMed ID: 30141223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.